Compare StocksJNJ vs MRNA

Johnson & Johnson (JNJ) vs Moderna, Inc. (MRNA)

JNJ
Johnson & Johnson
$227.19
VS
MRNA
Moderna, Inc.
$45.37

Rewards

JNJ
  • Johnson & Johnson has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 68.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Johnson & Johnson scores 90/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
MRNA

    Risks

    JNJ
    • Trailing P/E of 26.3x is 32% above the historical average of 20.0x — the stock trades at a premium to its own history.
    • PEG ratio of 2.95 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
    • 7 insider sales totaling $58.4M with no purchases in the past 3 months — insiders are reducing their exposure.
    MRNA
    • ROIC has declined by 61.0 percentage points over the observed period, which may signal competitive erosion.
    • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.

    Key Valuation Metrics

    Learn more →
    JNJ
    MRNA
    Valuation
    $19.31B
    Free Cash Flow
    $-20.00M
    3.53%
    FCF Yield
    -0.11%
    26.33
    Trailing P/E
    N/A
    17.87
    Forward P/E
    -9.86
    Quality & Moat
    15.32%
    ROIC
    -26.47%
    33.02%
    ROE
    -38.09%
    68.04%
    Gross Margin
    -69.89%
    2.95
    PEG Ratio
    N/A
    Balance Sheet Safety
    0.68
    Debt / Equity
    0.18
    N/A
    Interest Coverage
    N/A
    0.96
    Net Debt / EBITDA
    N/A
    2.36%
    Dividend Yield
    N/A
    JNJ: 5Ties: 1MRNA: 2
    JNJMRNA

    Historical Fundamentals

    Learn more →
    JNJ

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation.

    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation.

    $1 Retained Earnings Test

    Learn more →
    JNJ
    $0.91
    created per $1 retained over 3 years
    Mediocre Allocator
    Σ Retained
    $40.05B
    Δ Market Cap
    +$36.63B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    JNJ
    11.4% Margin of Safety
    Price is 11.4% below estimated fair value
    Current Price: $227.19
    Fair Value: $256.33
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    MRNA
    633.5% Overvalued
    Price is 633.5% above estimated fair value
    Current Price: $45.37
    Fair Value: $6.19
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    JNJ

    What growth rate is the market pricing in at $227?

    +8.8%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +13.2%

    The market implies +8.8% Owner Earnings growth, below historical trends — potential opportunity.

    Standard FCF implies a more demanding +13.2%, reflecting heavy growth investment expected to generate future returns.

    MRNA

    Requires positive FCF to compute implied growth rate.

    Economic Moat Score

    Learn more →
    JNJ
    90/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    JNJ
    -2.31
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    MRNA
    -3.72
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    JNJ
    Insiders 0.1%Institutions 76.2%Retail & Other 23.7%
    No. of Institutional Holders5,579
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    MRNA
    Insiders 7.3%Institutions 76.9%Retail & Other 15.8%
    No. of Institutional Holders992
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    JNJ
    0
    Buys (3M)
    1
    Buys (12M)
    Total value (12M): $257,688
    MORIKIS JOHN G
    Director
    $257,688
    @ $206.15 · 2025-11-26
    WEINBERGER MARK A
    Director
    $147,220
    @ $147.22 · 2024-12-12
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    JNJ
    7
    Sells (3M)
    12
    Sells (12M)
    Total value (12M): $101.23M
    DECKER ROBERT J
    Officer
    $1.01M
    @ $247.87 · 2026-02-27
    SCHMID TIMOTHY
    Officer
    $324,763
    @ $245.66 · 2026-02-20
    SCHMID TIMOTHY
    Officer
    $5.53M
    @ $244.33 · 2026-02-18
    SWANSON JAMES D
    Chief Technology Officer
    $15.11M
    @ $243.39 · 2026-02-17
    BROADHURST VANESSA
    Officer
    $1.51M
    @ $243.39 · 2026-02-17
    REED JOHN C
    Officer
    $13.11M
    @ $243.00 · 2026-02-17
    WOLK JOSEPH J
    Chief Financial Officer
    $21.77M
    @ $242.80 · 2026-02-17
    REED JOHN C
    Officer
    $4.19M
    @ $192.71 · 2025-10-17
    TAUBERT JENNIFER L
    Officer
    $10.04M
    @ $177.81 · 2025-09-04
    DUATO JOAQUIN BOIX
    Chief Executive Officer
    $22.55M
    @ $179.21 · 2025-08-22
    WOLK JOSEPH J
    Chief Financial Officer
    $2.98M
    @ $176.91 · 2025-08-15
    REED JOHN C
    Officer
    $3.13M
    @ $163.55 · 2025-07-17
    DECKER ROBERT J
    Officer
    $1.16M
    @ $165.88 · 2025-02-25
    SCHMID TIMOTHY
    Officer
    $62,928
    @ $156.15 · 2025-02-18
    WOLK JOSEPH J
    Chief Financial Officer
    $2.00M
    @ $153.89 · 2025-02-07
    DECKER ROBERT J
    Officer
    $930,113
    @ $165.06 · 2024-08-30
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    MRNA
    2
    Sells (3M)
    4
    Sells (12M)
    Total value (12M): $8.56M
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    KLINGER SHANNON THYME
    Officer
    $40,539
    @ $73.57 · 2024-09-09
    HOGE STEPHEN
    President
    $24,483
    @ $76.99 · 2024-09-03
    KLINGER SHANNON THYME
    Officer
    $8,777
    @ $76.99 · 2024-09-03
    MOCK JAMES M
    Chief Financial Officer
    $12,640
    @ $78.02 · 2024-08-29
    HOGE STEPHEN
    President
    $23,408
    @ $78.03 · 2024-08-29
    KLINGER SHANNON THYME
    Officer
    $12,640
    @ $78.02 · 2024-08-29
    MOCK JAMES M
    Chief Financial Officer
    $104,881
    @ $79.40 · 2024-08-28
    KLINGER SHANNON THYME
    Officer
    $104,722
    @ $79.39 · 2024-08-28
    HOGE STEPHEN
    President
    $21,363
    @ $84.11 · 2024-08-12
    AFEYAN NOUBAR BOGHOS
    Director
    $1.80M
    @ $119.96 · 2024-07-31
    AFEYAN NOUBAR BOGHOS
    Director
    $1.77M
    @ $117.80 · 2024-07-24
    AFEYAN NOUBAR BOGHOS
    Director
    $1.84M
    @ $122.84 · 2024-07-17
    HOGE STEPHEN
    President
    $1.82M
    @ $121.12 · 2024-07-15
    AFEYAN NOUBAR BOGHOS
    Director
    $1.76M
    @ $117.08 · 2024-07-10
    MOCK JAMES M
    Chief Financial Officer
    $81,465
    @ $118.24 · 2024-07-08
    AFEYAN NOUBAR BOGHOS
    Director
    $1.91M
    @ $127.22 · 2024-06-26
    AFEYAN NOUBAR BOGHOS
    Director
    $2.00M
    @ $133.57 · 2024-06-18
    HOGE STEPHEN
    President
    $2.07M
    @ $138.16 · 2024-06-17
    AFEYAN NOUBAR BOGHOS
    Director
    $2.21M
    @ $147.20 · 2024-06-12
    KLINGER SHANNON THYME
    Officer
    $766,785
    @ $148.09 · 2024-06-10
    AFEYAN NOUBAR BOGHOS
    Director
    $2.27M
    @ $151.25 · 2024-06-05
    MOCK JAMES M
    Chief Financial Officer
    $97,237
    @ $140.72 · 2024-06-03
    HOGE STEPHEN
    President
    $47,704
    @ $140.72 · 2024-06-03
    KLINGER SHANNON THYME
    Officer
    $17,168
    @ $140.72 · 2024-06-03
    MOCK JAMES M
    Chief Financial Officer
    $26,444
    @ $144.50 · 2024-05-29
    HOGE STEPHEN
    President
    $49,276
    @ $144.50 · 2024-05-29
    KLINGER SHANNON THYME
    Officer
    $26,444
    @ $144.50 · 2024-05-29
    AFEYAN NOUBAR BOGHOS
    Director
    $2.90M
    @ $145.08 · 2024-05-29
    KLINGER SHANNON THYME
    Officer
    $210,566
    @ $162.47 · 2024-05-28
    MOCK JAMES M
    Chief Financial Officer
    $105,283
    @ $162.47 · 2024-05-28
    AFEYAN NOUBAR BOGHOS
    Director
    $2.36M
    @ $157.57 · 2024-05-22
    HOGE STEPHEN
    President
    $1.91M
    @ $127.49 · 2024-05-15
    AFEYAN NOUBAR BOGHOS
    Director
    $1.91M
    @ $127.32 · 2024-05-15
    HOGE STEPHEN
    President
    $30,844
    @ $120.96 · 2024-05-10
    AFEYAN NOUBAR BOGHOS
    Director
    $1.83M
    @ $121.68 · 2024-05-08
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    JNJ
    FearGreed
    😐Neutral(57/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    MRNA
    FearGreed
    😨Fear(35/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    JNJ
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (57)
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (35)
    View JNJ Full AnalysisView MRNA Full Analysis